Nationwide Survey of Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive and/or Anticancer Drugs to Establish the Therapeutic Strategy to Prevent Severe Liver Injury.

Nationwide Survey of Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive and/or Anticancer Drugs to Establish the Therapeutic Strategy to Prevent Severe Liver Injury. - HBV Reactivation through Immunosuppressive and/or Anti-cancer Therapies

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002859

Enrollment

530

Registered

2009-12-08

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HBV carriers and HBV-infected patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HBV carriers and the patients with previous HBV infection receiving immunosuppressive and/or anti-cancer drugs

Exclusion criteria

Exclusion criteria: The patients receiving rituximab.

Design outcomes

Primary

Measure	Time frame
To clarrify the prevalence of HBV re-activation depending on the types of diseases and therapies	—

Secondary

Measure	Time frame
To clariffy the efficacy of entecavir on development of liver infury due to HBV re-activation.	—

Countries

Japan

Contacts

Public ContactNobuaki Nakayama

Saitama Medical University Gastroenterology & Hepatology

nobunaka@saitama-med.ac.jp049-276-1198

Outcome results